Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of mRNA-4157 alone and with pembrolizumab in resectable solid tumors
jRCT2033240236Phase 1Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label trial of intismeran autogene and pembrolizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), gastric adenocarcinoma and 1 more (3 arms), sponsored by Moderna Inc. Primary endpoint: Safety and tolerability. Started Jul 2024; status: active, not recruiting.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2033240236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033240236.